Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Gemcitabine-Refractory Biliary Tract Cancer
NCT01943864Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2013
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trametinib in biliary tract cancer (BTC) (2 arms), sponsored by GSK. Primary endpoint: Non-progressive Disease Rate at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
trametinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01943864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01943864.